A Study to Test Long-term Treatment With Spesolimab in Patients With Fistulising Crohn's Disease Who Took Part in Previous Trials

Study Purpose

The main objectives of this study are to evaluate the long-term safety of spesolimab in patients with perianal fistulising Crohn's disease who have completed treatment in parent trials and to evaluate the long-term efficacy of spesolimab in patients with perianal fistulising Crohn's disease, who have completed treatment in parent trials

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.

Searching Both is inclusive of interventional and observational studies.

Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Patient older than 18 years. 2. Has completed all treatments (placebo or active treatment) and the end of treatment (EOT) visit in the parent induction trial in fistulising Crohn's Disease (CD) and is willing and able to continue treatment in 1368-0007. 3. Has obtained an individual health benefit, per investigator judgement (such as fistula response or remission or other clinical improvement), from treatment in the parent trial. 4. Signed and dated written informed consent for 1368-0007 in accordance with GCP and local legislation prior to admission into the trial. 5. Women of childbearing potential (WOCBP) must be ready to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information.

Exclusion Criteria:

1. Have experienced treatment-limiting adverse events during induction treatment with study drug. 2. Have developed any condition which meets the exclusion criteria from the original induction study. 3. Any condition which in the opinion of the investigator affects the safety or ability to participate in this trial

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.


Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Boehringer Ingelheim
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Overall Status Recruiting
Countries Austria, Belgium, Germany, Korea, Republic of, Netherlands

The disease, disorder, syndrome, illness, or injury that is being studied.

Crohn Disease
Study Website: View Trial Website
Arms & Interventions


Experimental: Spesolimab arm


Drug: - Spesolimab


Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

AKH - Medical University of Vienna, Wien, Austria




AKH - Medical University of Vienna

Wien, , 1090

UZ Leuven, Leuven, Belgium




UZ Leuven

Leuven, , 3000

Site Contact

Marc Ferrante


+32 16 34 88 56

Liège, Belgium




Centre Hospitalier Universitaire de Liège

Liège, , 4000

Site Contact

Edouard Louis


+32 43667256

Universitätsklinikum Erlangen, Erlangen, Germany


Active, not recruiting


Universitätsklinikum Erlangen

Erlangen, , 91054

Universitätsklinikum Ulm, Ulm, Germany


Active, not recruiting


Universitätsklinikum Ulm

Ulm, , 89081

Inje University Haeundae Paik Hospital, Busan, Korea, Republic of




Inje University Haeundae Paik Hospital

Busan, , 612-896

Site Contact

Tae-Oh Kim


82 10 9330 2333

Amsterdam UMC, Locatie AMC, Amsterdam, Netherlands




Amsterdam UMC, Locatie AMC

Amsterdam, , 1105 AZ

Site Contact

Geert D'Haens


+31 (0)20 566 3534